(Q43609548)

25 November 2017

title

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease (English)

1 reference

25 November 2017

0 references

G T Grossberg

1

1 reference

25 November 2017

J T Olin

series ordinal

2

1 reference

25 November 2017

M Somogyi

series ordinal

3

1 reference

25 November 2017

X Meng

series ordinal

4

1 reference

25 November 2017

publication date

11 February 2011

1 reference

International Journal of Clinical Practice

25 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 November 2017

volume

65

1 reference

25 November 2017

issue

4

1 reference

25 November 2017

page(s)

465-471

1 reference

Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

Rationale for transdermal drug administration in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02641.X

10.1111/J.1742-1241.2011.02641.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference